Search
Now showing items 1-8 of 8
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia
(2012)
BACKGROUND:
Acute myeloid leukemia (AML) is a heterogeneous disease with respect to presentation and clinical outcome. The prognostic value of recently identified somatic mutations has not been systematically evaluated ...
How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia?
(2012)
Acute myeloid leukemia (AML) is the most common acute leukemia diagnosed in adults, and the majority of patients with AML die from relapsed disease. Although many studies over the past 4 decades have identified disease ...
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression
(2012)
Recurrent somatic ASXL1 mutations occur in patients with myelodysplastic syndrome, myeloproliferative neoplasms, and acute myeloid leukemia, and are associated with adverse outcome. Despite the genetic and clinical data ...
Effect of serum lipoproteins on stereoselective halofantrine metabolism by rat hepatocytes
(2012)
Experimental hyperlipidemia has shown to decrease cytochrome P450 3A4 and 2C11 expression and to increase liver concentrations and the plasma protein binding of halofantrine (HF) enantiomers. The present study examined the ...
OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance
(2012)
OSI-930, a dual c-Kit and KDR tyrosine kinase inhibitor, is reported to have undergone a Phase I dose escalation study in patients with advanced solid tumors. A series of fifteen pyridyl and phenyl analogues of OSI-930 ...
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis
(2012)
Abstract
Aging is characterized by clonal expansion of myeloid-biased hematopoietic stem cells and by increased risk of myeloid malignancies. Exome sequencing of three elderly females with clonal hematopoiesis, demonstrated ...
CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900
(2012)
We determined the prognostic relevance of CD25 (IL-2 receptor-α) expression in 657 patients (≤ 60 years) with de novo acute myeloid leukemia (AML) treated in the Eastern Cooperative Oncology Group trial, E1900. We identified ...
The role of mutations in epigenetic regulators in myeloid malignancies
(2012)
The role of mutations in epigenetic regulators in myeloid malignancies.
Recent genomic studies have identified novel recurrent somatic mutations in patients with myeloid malignancies, including myeloproliferative ...